Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 12—December 2005

Human Granulocytic Anaplasmosis and Anaplasma phagocytophilum

J. Stephen Dumler*Comments to Author , Kyoung-Seong Choi*, Jose Carlos Garcia-Garcia*, Nicole S. Barat*, Diana G. Scorpio*, Justin W. Garyu*, Dennis J. Grab*, and Johan S. Bakken†‡
Author affiliations: *Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; †University of Minnesota at Duluth, Duluth, Minnesota, USA; ‡St. Luke's Hospital, Duluth, Minnesota, USA

Main Article


Metaanalysis of clinical manifestations and laboratory abnormalities in patients with human granulocytic anaplasmosis*

Characteristics All
North America
Median %† Mean % n‡ Mean % n Mean % n
Symptom or sign
Fever 100 92 480 92 448 98 66
Myalgia 74 77 514 79 448 65 66
Headache 89 75 378 73 289 89 66
Malaise 93 94 90 96 271 47 15
Nausea 44 38 256 36 207 47 49
Vomiting 20 26 90 34 41 19 49
Diarrhea 13 16 90 22 41 10 49
Cough 13 19 260 22 207 10 49
Arthralgias 58 46 497 47 448 37 49
Rash 3 6 685 6 289 4 53
Stiff neck 11 18 22 22 18 0 4
Confusion 9 17 211 17 207 0 4
Laboratory abnormality
Leukopenia 38 49 329 50 282 47 47
Thrombocytopenia 71 71 329 72 282 64 47
Elevated serum AST or ALT§ 74 71 170 79 123 51 47
Elevated serum creatinine 15 43 72 49 59 0 13

*Data from references 5, 6, 815.

†Median percentage of patients with feature among all reports.

‡Number of patients with data available for metaanalysis.

§AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Main Article

  1. Chen  S-M, Dumler  JS, Bakken  JS, Walker  DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol. 1994;32:58995.PubMed
  2. Bakken  JS, Dumler  JS, Chen  SM, Eckman  MR, Van Etta  LL, Walker  DH. Human granulocytic ehrlichiosis in the upper midwest United States. A new species emerging? JAMA. 1994;272:2128. DOIPubMed
  3. Dumler  JS, Barbet  AF, Bekker  CP, Dasch  GA, Palmer  GH, Ray  SC, Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol. 2001;51:214565. DOIPubMed
  4. Walker  DH, Dumler  JS. Emergence of ehrlichioses as human health problems. Emerg Infect Dis. 1996;2:1829. DOIPubMed
  5. Bakken  JS, Krueth  J, Wilson-Nordskog  C, Tilden  RL, Asanovich  K, Dumler  JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA. 1996;275:199205. DOIPubMed
  6. Aguero-Rosenfeld  ME, Horowitz  HW, Wormser  GP, McKenna  DF, Nowakowski  J, Munoz  J, Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med. 1996;125:9048.PubMed
  7. Hardalo  C, Quagliarello  V, Dumler  JS. Human granulocytic ehrlichiosis in Connecticut: report of a fatal cases. Clin Infect Dis. 1995;21:9104. DOIPubMed
  8. Lotric-Furlan  S, Petrovec  M, Avsic-Zupanc  T, Strle  F. Human granulocytic ehrlichiosis in Slovenia. Ann N Y Acad Sci. 2003;990:27984. DOIPubMed
  9. Blanco  JR, Oteo  JA. Human granulocytic ehrlichiosis in Europe. Clin Microbiol Infect. 2002;8:76372. DOIPubMed
  10. Bjoersdorff  A, Wittesjo  B, Berglun  J, Massung  RF, Eliasson  I. Human granulocytic ehrlichiosis as a common cause of tick-associated fever in Southeast Sweden: report from a prospective clinical study. Scand J Infect Dis. 2002;34:18791. DOIPubMed
  11. Belongia  EA, Gale  CM, Reed  KD, Mitchell  PD, Vandermause  M, Finkel  MF, Population-based incidence of human granulocytic ehrlichiosis in northwestern Wisconsin, 1997–1999. J Infect Dis. 2001;184:14704. DOIPubMed
  12. Belongia  EA, Reed  KD, Mitchell  PD, Chyou  PH, Mueller-Rizner  N, Finkel  MF, Clinical and epidemiological features of early Lyme disease and human granulocytic ehrlichiosis in Wisconsin. Clin Infect Dis. 1999;29:14727. DOIPubMed
  13. Wallace  BJ, Brady  G, Ackman  DM, Wong  SJ, Jacquette  G, Lloyd  EE, Human granulocytic ehrlichiosis in New York. Arch Intern Med. 1998;158:76973. DOIPubMed
  14. Lotric-Furlan  S, Petrovec  M, Avsic-Zupanc  T, Strle  F. Comparison of patients fulfilling criteria for confirmed and probable human granulocytic ehrlichiosis. Scand J Infect Dis. 2004;36:81722. DOIPubMed
  15. Bakken  JS. Clinical diagnosis and treatment of human granulocytic anaplasmosis. In: Abstracts of the 4th International Conference on Rickettsiae and Rickettsial Diseases, Logrono, Spain, 2005 Jun 18–21. Abstract O-34.
  16. Bakken  JS, Goellner  P, Van Etten  M, Boyle  DZ, Swonger  OL, Mattson  S, Seroprevalence of human granulocytic ehrlichiosis (HGE) and risk factors associated with infection among residents in northwestern Wisconsin. Clin Infect Dis. 1998;27:14916. DOIPubMed
  17. Aguero-Rosenfeld  ME, Donnarumma  L, Zentmaier  L, Jacob  J, Frey  M, Noto  R, Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol. 2002;40:26125. DOIPubMed
  18. IJdo  JW, Meek  JI, Cartter  ML, Magnarelli  LA, Wu  C, Tenuta  SW, The emergence of another tickborne infection in the 12-town area around Lyme, Connecticut: human granulocytic ehrlichiosis. J Infect Dis. 2000;181:138893. DOIPubMed
  19. Lepidi  H, Bunnell  JE, Martin  ME, Madigan  JE, Stuen  S, Dumler  JS. Comparative pathology and immunohistology associated with clinical illness after Ehrlichia phagocytophila–group infections. Am J Trop Med Hyg. 2000;62:2937.PubMed
  20. Brodie  TA, Holmes  PH, Urquhart  GM. Some aspects of tick-borne diseases of British sheep. Vet Rec. 1986;118:4158. DOIPubMed
  21. Gribble  DH. Equine ehrlichiosis. J Am Vet Med Assoc. 1969;155:4629.PubMed
  22. Lin  M, Rikihisa  Y. Ehrlichia chaffeensis and Anaplasma phagocytophilum lack genes for lipid A biosynthesis and incorporate cholesterol for their survival. Infect Immun. 2003;71:532431. DOIPubMed
  23. Ohashi  N, Zhi  N, Lin  Q, Rikihisa  Y. Characterization and transcriptional analysis of gene clusters for a type IV secretion machinery in human granulocytic and monocytic ehrlichiosis agents. Infect Immun. 2002;70:212838. DOIPubMed
  24. Caturegli  P, Asanovich  KM, Walls  JJ, Bakken  JS, Madigan  JE, Popov  S, ankA: an Ehrlichia phagocytophila group gene encoding a protein antigen with ankyrin-like repeats. Infect Immun. 2000;68:527783. DOIPubMed
  25. Herron  MJ, Nelson  CM, Larson  J, Snapp  KR, Kansas  GS, Goodman  JL. Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. Science. 2000;288:16536. DOIPubMed
  26. Park  J, Choi  K-S, Dumler  JS. Major surface protein 2 (Msp2) of Anaplasma phagocytophilum facilitates adherence to granulocytes. Infect Immun. 2003;71:401825. DOIPubMed
  27. Webster  P, IJdo  JW, Chicoine  LM, Fikrig  E. The agent of human granulocytic ehrlichiosis resides in an endosomal compartment. J Clin Invest. 1998;101:193241. DOIPubMed
  28. Scorpio  DG, Caspersen  K, Ogata  H, Park  J, Dumler  JS. Restricted changes in major surface protein-2 (msp2) transcription after prolonged in vitro passage of Anaplasma phagocytophilum. BMC Microbiol. 2004;4:1. DOIPubMed
  29. Park  J, Kim  KJ, Choi  KS, Grab  DJ, Dumler  JS. Anaplasma phagocytophilum AnkA binds to granulocyte DNA and nuclear proteins. Cell Microbiol. 2004;6:74351. DOIPubMed
  30. Dumler  JS, Trigiani  ER, Bakken  JS, Aguero-Rosenfeld  ME, Wormser  GP. Serum cytokine responses during acute human granulocytic ehrlichiosis. Clin Diagn Lab Immunol. 2000;7:68.PubMed
  31. Martin  ME, Caspersen  K, Dumler  JS. Immunopathology and ehrlichial propagation are regulated by interferon gamma (IFNγ) and interleukin-10 (IL-10) in a murine model of human granulocytic ehrlichiosis (HGE). Am J Pathol. 2001;158:18818. DOIPubMed
  32. Klein  MB, Hu  S, Chao  CC, Goodman  JL. The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. J Infect Dis. 2000;182:2005. DOIPubMed
  33. Akkoyunlu  M, Malawista  SE, Anguita  J, Fikrig  E. Exploitation of interleukin-8-induced neutrophil chemotaxis by the agent of human granulocytic ehrlichiosis. Infect Immun. 2001;69:557788. DOIPubMed
  34. Carlyon  JA, Abdel-Latif  D, Pypaert  M, Lacy  P, Fikrig  E. Anaplasma phagocytophilum utilizes multiple host evasion mechanisms to thwart NADPH oxidase-mediated killing during neutrophil infection. Infect Immun. 2004;72:477283. DOIPubMed
  35. Carlyon  JA, Chan  WT, Galan  J, Roos  D, Fikrig  E. Repression of rac2 mRNA expression by Anaplasma phagocytophila is essential to the inhibition of superoxide production and bacterial proliferation. J Immunol. 2002;169:700918.PubMed
  36. Choi  K-S, Dumler  JS. Early induction and late abrogation of respiratory burst in A. phagocytophilum–infected neutrophils. Ann N Y Acad Sci. 2003;990:48893. DOIPubMed
  37. Ge  Y, Yoshiie  K, Kuribayashi  F, Lin  M, Rikihisa  Y. Anaplasma phagocytophilum inhibits human neutrophil apoptosis via upregulation of bfl-1, maintenance of mitochondrial membrane potential and prevention of caspase 3 activation. Cell Microbiol. 2005;7:2938. DOIPubMed
  38. Choi  K-S, Garyu  J, Park  J, Dumler  JS. Diminished adhesion of Anaplasma phagocytophilum–infected neutrophils to endothelial cells is associated with reduced leukocyte surface selectin expression. Infect Immun. 2003;71:458694. DOIPubMed
  39. Choi  KS, Grab  DJ, Dumler  JS. Anaplasma phagocytophilum infection induces protracted neutrophil degranulation. Infect Immun. 2004;72:36803. DOIPubMed
  40. Garyu  JW, Choi  KS, Grab  DJ, Dumler  JS. Defective phagocytosis in Anaplasma phagocytophilum–infected neutrophils. Infect Immun. 2005;73:118790. DOIPubMed

Main Article

Page created: February 02, 2012
Page updated: February 02, 2012
Page reviewed: February 02, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.